News

Xoma Royalty to Acquire Lava Therapeutics

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.
LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty
LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA), under which XOMA will acquire LAVA in a cash and milestone-based deal.
Xoma Royalty to Acquire Lava Therapeutics
Xoma Royalty has agreed to acquire Lava Therapeutics.
Xoma Royalty to Acquire Lava Therapeutics, End Development of Lead Candidate
The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics
XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA Therapeutics N.V. (NASDAQ:LVTX)—through separate deals that combine upfront cash offers with contingent value rights (CVRs).
LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty
Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds from LAVA’s partnered assets and any out-licensing or sale of unpartnered programs.

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...
The Pharma Letter1d

Promise of gamma delta bispecific antibodies prompts XOMA acquisition

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

XOMA Royalty to acquire HilleVax and LAVA Therapeutics in separate deals

In a separate transaction, XOMA Royalty will acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, plus a CVR representing the right to receive 75% of net proceeds related to LAVA’s ...